Cancer Immunotherapy: Volume 90
Academic Press
Published on 19. May 2006
Book
Hardback
400 pages
978-0-12-022489-0 (ISBN)
Description
For some time immunotherapy has been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, the approach needs considerable refinement. Whilst some programmes are looking to increase the understanding of molecular and cellular mechanisms underlying the stimulation of antitumor immunity, others are trying to find the most appropriate clinical setting that will reveal the role of the immune system in combating cancer. Among the most important discoveries have been tumor-specific antigens.
This thematic volume highlights some key issues and discusses where they may move forward. It has been put together by two leading cancer immunotherapists from two eminent institutions that focus on cancer research.
This thematic volume highlights some key issues and discusses where they may move forward. It has been put together by two leading cancer immunotherapists from two eminent institutions that focus on cancer research.
Reviews / Votes
PRAISE FOR THE SERIES:"...among the most active volumes in the libraries of our universities and institutions." --SCIENCE
"A provocative and scholarly review of research." --JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
More details
Series
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
Immunologists, research oncologists, pathologists, and cell biologists
Illustrations
Illustrated
Dimensions
Height: 229 mm
Width: 152 mm
Weight
770 gr
ISBN-13
978-0-12-022489-0 (9780120224890)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions

James Dranoff Glen Allison | Glen Dranoff
Cancer Immunotherapy
E-Book
05/2014
Academic Press
€155.00
Available for download
Persons
Author
Howard Hughes Medical Institute Memorial Sloan-Kettering Cancer Center, New York, U.S.A.
Dana-Farber Cancer Institute, Boston, MA, U.S.A.
Content
Engineered cellular vaccines
Blockade of T cell checkpoints.
Serex in the identification of target antigens
New approaches to tumor immunotherapy
Melanoma antigens
Antibodies and chimeric molecules
Tumor Immunosurveillance
Dendritic Cells
Strategies for Tumor Vaccination
DNA vaccines
Blockade of T cell checkpoints.
Serex in the identification of target antigens
New approaches to tumor immunotherapy
Melanoma antigens
Antibodies and chimeric molecules
Tumor Immunosurveillance
Dendritic Cells
Strategies for Tumor Vaccination
DNA vaccines